Neuropathic pain:
Neuropathic pain affects around 10% of the world’s population – about 800 million people. It is the largest unmet need in pain treatment globally.
It is most commonly caused by chemotherapy, diabetes, surgery, infections like shingles, and physical trauma including car accidents.
Current treatments are suboptimal and have a host of detrimental side effects. Most current drugs are out of patent, and there’s a significant lack of new candidates in the pipeline.
Introducing
RM191A: A revolutionary topical treatment for neuropathic pain
We recently completed a phase 2a clinical trial which evaluated RM191A gel in patients with chronic, severe, treatment-resistant peripheral neuropathic pain.
RM191A (BioCuplex™) in topical formulation demonstrated compelling efficacy and an excellent safety profile. It has no known side‑effects, no known interactions with common pain medications, and is non‑addictive.
Results of this study will be published soon.